Who Owns LENZ Therapeutics Stock?
NASDAQ: LENZHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 111.76%
- Institutions (% of float)
- 114.80%
- Held by insiders
- 2.65%
- Institutional holders
- 195
- Institutions 97.4%
- Insiders 2.6%
- Public and other 0.0%
Who owns LENZ Therapeutics stock?
Institutional investors own about 111.8% of LENZ Therapeutics's shares, spread across 195 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 2.65% of LENZ.
The largest institutional holders are RA Capital Management, L.P. (13.30%), Alpha Wave Global, LP (11.50%) and FMR, LLC (11.33%). Together, the top 10 institutions control 73.9% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their LENZ positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of LENZ
| Institution | Shares | % Held | Change |
|---|---|---|---|
| RA Capital Management, L.P. | 4.18M | 13.30% | 0.0% |
| Alpha Wave Global, LP | 3.61M | 11.50% | 0.0% |
| FMR, LLC | 3.56M | 11.33% | -1.1% |
| Versant Venture Management, LLC | 2.66M | 8.46% | 0.0% |
| Blackrock Inc. | 2.29M | 7.30% | +15.9% |
| Squarepoint Ops LLC | 1.75M | 5.56% | +16.0% |
| Aberdeen Group plc | 1.55M | 4.93% | +33.9% |
| Millennium Management Llc | 1.51M | 4.80% | +73.5% |
| Vanguard Capital Management LLC | 1.10M | 3.49% | +5.4% |
| 72 Investment Holdings, LLC | 1.02M | 3.24% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of LENZ
| Fund | Shares | % Held |
|---|---|---|
| abrdn Healthcare Investors | 1.05M | 3.33% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 819.61K | 2.61% |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 810.72K | 2.58% |
| iShares Trust-iShares Russell 2000 ETF | 530.63K | 1.69% |
| abrdn Life Sciences Investors | 500.70K | 1.59% |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 406.40K | 1.29% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 253.11K | 0.81% |
| Fidelity Covington Trust-Fidelity Enhanced Small Cap Core ETF | 235.86K | 0.75% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 225.78K | 0.72% |
| iShares Trust-iShares Biotechnology ETF | 203.92K | 0.65% |
Frequently asked questions
Who is the largest shareholder of LENZ Therapeutics?
RA Capital Management, L.P. is the largest institutional shareholder of LENZ, owning 13.30% of shares outstanding (4.18M shares) as of its latest 13F filing.
What percentage of LENZ Therapeutics is owned by institutions?
Institutions own about 111.8% of LENZ shares and 114.8% of the public float.
How much of LENZ Therapeutics do insiders own?
Insiders, such as officers and directors, own about 2.65% of LENZ shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.